Articles By Jack Cush, MD
Antibiotics May Increase Inflammatory Arthritis Risk
A Danish registry study has shown that amongst those patients who develop inflammatory arthritis (IA), antibiotics use was more frequent when compared to the background population (BP).
Read Article
All in the Family (8.23.2024)
Dr. Jack Cush picks highlight reports from the past week on RheumNow.com, with reports on the challenge of lupus nephritis, perplexing skin issues, you don't know JAK (about Tyk) and the value of a good family history.
Read Article
Studies on Psoriatic Arthritis Prevention
Psoriatic arthritis (PsA) is a sequelae to chronic skin psoriasis. Whether cutaneous psoriasis is the pre-clinical phase of what may become PsA is oft debated and has been inadequately researched, largely using claims data or retrospective data sets.
Read Article
A Family History of Arthritis?
Using data from the population based All of Us (AoU) Research Program, a self reported history of arthritis and related conditions was associated with an increased risk for arthritis, osteoporosis, and carpal tunnel syndrome.
Read Article
Predictors of Pregnancy Outcomes in Systemic Lupus Erythematosus
A systematic review of preconception predictors of pregnancy outcomes in women with systemic lupus erythematosus (SLE) highlighted lupus nephritis, chronic hypertension, SLE disease activity and secondary antiphospholipid syndrome as predictors of adverse pregnancy outcomes. Pregnancies in women with SLE have historically been described as challenging, both because of the risk of disease flare and of adverse pregnancy outcomes.
Read Article
Pulse Steroids with Tocilizumab in Giant Cell Arteritis
A pilot study assessed pulse methoprednisolone with weekly subcutaneous tocilizumab (TCZ) in patients with large vessel-GCA (LV-GCA) and showed that a sizeable minority will relapse after the TCZ is discontinued.
Read Article
Sequential Belimumab and Rituximab in SLE
Could disease control in active systemic lupus erythematosus (SLE) patients be improved by the sequential use of subcutaneous belimumab (BEL) and intravenous rituximab (RTX)? A double blind trial has shown that sequential BEL and RTX was not superior to BEL alone in SLE.
Read Article
ACR Applauds Lower Negotiated Prices for Common Arthritis Drugs
The American College of Rheumatology praised the recent announcement from the Centers for Medicare & Medicaid Services (CMS) that their initial drug pricing negotiations have reduced costs for select medications, including significantly lower prices for Enbrel and Stelara, which are frequently used to treat rheumatic diseases.
Read Article
Higher Cancer Rates (8.16.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.
Read Article
ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis
Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.
Read Article